According to a study published in Scientific Reports, an international research team has identified a specific panel of blood proteins that sheds light on why the corticosteroid prednisone suppresses childhood growth and harms bone health while treating Duchenne muscular dystrophy (DMD). Researchers at Binghamton University and Carleton University found that unlike prednisone, a drug called vamorolone successfully improves motor outcomes without triggering this adverse bone and cartilage biomarker signature.
Clinical Trial Design and Patient Crossover Data
The findings stem from a double-blind clinical trial tracking boys with Duchenne muscular dystrophy aged four to seven years old. During the initial 24-week period of the study, participants received either a placebo, prednisone administered at 0.75 mg/kg/day, or vamorolone administered at a 6 mg/kg/day dose. Vamorolone was specifically developed as an alternative therapy for DMD. In the subsequent 24-week phase, individuals originally assigned to the placebo or prednisone groups transitioned over to vamorolone treatment, while the initial vamorolone cohort maintained their regimen.
Pro Tip: Tracking patients through a treatment crossover period allows researchers to distinguish between disease progression and direct, reversible drug impacts on pediatric biomarkers, according to study statisticians.
Biomarker Suppression and the Prednisone-Specific Signature
According to the Scientific Reports findings, prednisone significantly suppressed both established clinical markers and newly identified proteins linked to bone formation, bone turnover, and growth-plate activity. The research team first evaluated four standard clinical laboratory markers: alkaline phosphatase (ALP), osteocalcin, procollagen type I N-terminal propeptide (P1NP), and collagen type I C-terminal telopeptide (CTX1). All four metrics declined during prednisone administration, held steady under vamorolone and placebo, and rebounded quickly toward baseline levels once patients transitioned away from prednisone.
Beyond standard lab tests, the broad protein screen uncovered 10 additional protein measurements depressed by prednisone. These included collagen-related molecules and structural components vital for bone and cartilage. Utkarsh Dang, lead statistician of the study and a professor at Carleton University’s Department of Health Sciences, noted that watching these markers return to baseline after discontinuing prednisone points to a reversible drug effect rather than natural disease progression.
Protecting the Childhood Growth Plate
Many of the newly isolated proteins connect directly to osteoblasts—the cells responsible for building bone—and specialized growth-plate cells that drive bone lengthening in children. Human biomarker data shows that traditional corticosteroids like prednisone promote the loss of these essential cells and disrupt osteoblast function. Vamorolone, by contrast, failed to produce this suppressive signature, pointing to a mechanism that better preserves osteoblasts and growth plates, which aligns with clinical observations of steady linear growth during vamorolone treatment.
“Prednisone remains an important therapy for Duchenne muscular dystrophy, but its effects on growth and bone health are a major concern for children and families,” said Eric P. Hoffman, senior author of the study, associate dean for research and research development, and professor of pharmaceutical sciences at Binghamton University. Hoffman emphasized that while both drugs improved motor outcomes in the trial, only prednisone produced the adverse biomarker pattern.
Future Directions and Limitations in Pediatric Care
Researchers caution that blood biomarkers do not automatically equate to long-term clinical outcomes. Because the study evaluated a smaller subset of a broader trial population focused specifically on young boys with Duchenne muscular dystrophy, further research is required. Extended studies involving larger cohorts will be necessary to determine whether these protein signatures reliably predict future fracture reduction or long-term skeletal strength, and whether girls or children with other pediatric conditions show similar patterns.
“These proteins could eventually provide a practical way to monitor the biological health of the growth plate during treatment,” Hoffman stated. He added that the biomarkers may also prove useful in other pediatric conditions where corticosteroids, chronic illness, or experimental treatments interfere with standard growth patterns.
Did You Know?
Duchenne muscular dystrophy is an X-linked recessive disorder caused by mutations in the dystrophin gene. It affects approximately 1.4 per 10,000 US males aged 5 to 24 years, making it the most common form of pediatric muscular dystrophy, according to population-based data from the MD STARnet surveillance network published in public health records.
Frequently Asked Questions
What is the main difference between prednisone and vamorolone regarding bone health?
According to the Scientific Reports study, prednisone suppresses established and newly identified blood biomarkers associated with bone formation, turnover, and growth-plate activity. Vamorolone does not produce this suppressive biomarker signature while still improving motor outcomes in young boys with Duchenne muscular dystrophy.
Are these biomarker changes permanent?
No. When clinical trial participants who had received prednisone transitioned to vamorolone, the suppressed biomarkers returned toward their pre-treatment levels, indicating a reversible drug effect rather than permanent disease progression.
Can these biomarkers be used for conditions other than Duchenne muscular dystrophy?
Researchers suggest that these proteins could eventually monitor growth-plate health in other pediatric conditions where corticosteroids, chronic illnesses, or investigational therapies disrupt normal childhood growth.
Stay Informed: Explore our archive for more updates on pediatric clinical trials, neuromuscular research, and advances in rare disease therapies. Join the conversation by sharing your thoughts or questions below.
Keep reading